ID;Term;Depth;IC Nuno;IC zhou;IC sanchez;IC resnik;IC RZ;IC Rnormalized;IC Nuno org;Annotated Genes Set number
GO:0016525;negative regulation of angiogenesis;8.0;0.811012628672052;0.780506314336026;9.32314260294094;151.1079732353669;5.192106149009898;0.005057447875840929;0.6405245499179943;[FASLG, PRL, HHEX, EMILIN1, HOXA5, CCR2, DCN, HGS, CX3CR1, THBS1, TGFB2, PLK2, TIE1, CXCL10, TEK, PF4]
GO:0042416;dopamine biosynthetic process;8.0;0.9326813400603323;0.8413406700301662;9.590783924509275;507.8534772351106;7.474488534686424;0.01699739884460309;0.7572456912631272;[NR4A2, TGFB2, GPR37, GCH1]
GO:0014068;positive regulation of phosphatidylinositol 3-kinase signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;5.602686357784832;0.007979625599047746;0.6615216408886768;[CCL5, PDGFD, PDGFC, FYN, PDGFRB, TGFB2, F2R, PTK2, DCN, FGR, GH1, KIT, CD28, PTPN6, TEK]
GO:0008584;male gonad development;5.0;1.0;0.7902410118609202;9.628524252492122;50.96471695749156;5.2552850506314295;0.001705743211299806;0.5589965337459591;[HMGB2, LRP2, MEA1, HOXA11, HOXA10, PDGFRB, LHCGR, TGFB2, BIK, INHBA, EIF2S2, SFRP2, NASP, MSH2, KIT]
GO:0009792;embryo development ending in birth or egg hatching;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;21.803048026859194;4.530049555519983;7.297283959896867E-4;0.5219079567990602;[TPM1, MSH2, EPB41L5, PLCG1, TGFB2, EIF2S2, MAFF, PTPRR, TMEM100, HHEX, TIE1]
GO:0032570;response to progesterone;6.0;0.9326813400603323;0.7894609826203107;9.548481544818586;105.99106082751567;6.166155715036245;0.0035474254201351726;0.6384578026126634;[GABRB1, TGFB2, TGFB1, CAV1, PTGER2, FOS, THBS1, CLDN4, TLR2]
GO:0045124;regulation of bone resorption;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;23.47587490287836;6.139487467954083;7.857164060836016E-4;0.6370939872166814;[CALCA, TFRC, SYK, ITGB3, TNFAIP3, TNFRSF11A, TMEM64, INPP5D, TNFSF11, CSK]
GO:0090051;negative regulation of cell migration involved in sprouting angiogenesis;11.0;1.0;0.9324289523296623;9.628524252492122;662.774530299232;7.069023426578259;0.02218246707076338;0.7939391391080821;[THBS1]
GO:0045766;positive regulation of angiogenesis;7.0;0.811012628672052;0.7564256795932265;9.303101852057495;134.49314513679974;4.7081694254602375;0.0045013645317563845;0.5916953686275062;[NRP1, CDH5, C3AR1, CTSH, GHSR, ANXA1, ANXA3, GAB1, SFRP2, IL1B, ADAM12, AGTR1, CHI3L1, ENG, CX3CR1, C5AR1, PTGS2, DLL1, THBS1, CXCR2, PLCG1, JUP, PLK2, TNFSF12, LRG1, TEK]
GO:0042535;positive regulation of tumor necrosis factor biosynthetic process;8.0;1.0;0.875;9.628524252492122;857.3444905607055;7.379178354882098;0.028694548539119222;0.7523715242355574;[TLR1, AZU1, TLR4, THBS1, CCR2]
GO:0000187;activation of MAPK activity;13.0;0.811012628672052;0.8680612791036626;9.526741558182179;3706.2450018205795;4.759793790865545;0.12404468480698592;0.705971040585548;[, LRRK2, TNF, GHR, PROK2, TNFSF11, MAP4K1, MAP2K2, SYK, DUSP6, IL1B, KIT, TLR4, C5AR1, FPR1, CXCR4, TGFA, IQGAP3, THBS1, NTF3, CCL19, DRD4, MAP2K6, EGF, MAPK14, CD40LG, CSPG4, PKN1]
GO:0030307;positive regulation of cell growth;6.0;0.6954798709641801;0.6708602480722345;8.712233520617966;80.64681300048527;4.733648510761223;0.0026991762537066665;0.5651993175676412;[CYFIP1, NRP1, CPNE5, CXCL16, RPS6KA1, AKT1, AVPR1A, SFRP2, S100A8, HBEGF, TAF9, PAK1, SFN, TGFB2, SYT2, CXCL12]
GO:0002479;antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent;6.0;1.0;0.8231203125901445;9.628524252492122;33.24930607151726;6.518977089658987;0.0011128243517809471;0.6565011041187423;[CHUK, ITGB5, CD36, FCGR1B]
GO:0001666;response to hypoxia;5.0;0.811012628672052;0.6957473261969462;9.117698628726131;21.16160540946;4.1860866471696125;7.082598888462125E-4;0.5043176776701113;[MPL, PHB2, SLC8A1, MYB, AKT1, ACTN4, ATP1B1, CLDN3, ABCB4, PSEN2, DPP4, EGR1, TGFB2, TGFB1, CAV1, NR4A2, CXCL12, NOX4, CD24, ALAD, MYOCD, ADSL, KCND2, AGTRAP, TGFBR3, IL1B, TLR2, CXCR4, KCNA5, PTGS2, THBS1, PAK1, TEK]
GO:0046580;negative regulation of Ras protein signal transduction;9.0;0.8259837884571596;0.8092325194088689;9.394909401310617;288.24654468039586;5.885253329569843;0.009647352445404638;0.6972127541467594;[STMN1, NUP62, TGFB2, ARAP3, BCL6, FBP1]
GO:0030823;regulation of cGMP metabolic process;9.0;0.7586651285174919;0.775573189439035;9.392135474427892;212.55514157362143;6.444869117505266;0.00711402930126111;0.7258315315665724;[PDE5A, GUCA1C, THBS1]
GO:0001942;hair follicle development;4.0;1.0;0.75;9.628524252492122;22.36266381479647;6.166155715036245;7.48458232790436E-4;0.5653374900225189;[TGFB2, INHBA, CELSR1, APCDD1, LGR4]
GO:0030308;negative regulation of cell growth;6.0;0.6913464685778243;0.6687935468790567;8.673012807464685;80.89021177018715;4.623782033182691;0.0027073225914839173;0.5595807407949613;[CDA, NRP1, SEMA5B, CDKN1A, ARHGAP4, TCHP, PPP2R1A, TNR, DCC, PSRC1, SFRP2, NDUFS3, FBP1, PAK1, TGFB2, TGFB1, CDKN2C, SEMA4B, INHBA, BCL6, SIPA1]
GO:0001701;in utero embryonic development;7.0;1.0;0.8509193652572005;9.628524252492122;22.496195207419138;4.63541007117781;7.529274083310655E-4;0.5879744518658467;[TPM1, MSH2, EPB41L5, PLCG1, EIF2S2, MAFF, PTPRR, TMEM100, HHEX, TIE1]
GO:0050671;positive regulation of lymphocyte proliferation;8.0;0.7436939687323844;0.7468469843661922;9.271849308553389;262.65490618866494;4.886724499458715;0.00879082333606575;0.6249073181582478;[CD86, TFRC, CD80, MPL, PYCARD, IL6R, ICOSLG, MEF2C, FLT3LG, MIF, MSH6, PRKCQ, CARD11, CD274, BLM, HHLA2, CORO1A, NCKAP1L, BST1, PTPRC, BCL6, CD28, CD24, CD320, CDKN1A, CD3E, TNFSF13B, CCR2, HLA-DPA1, HAVCR2, ANXA1, SYK, FCRL3, PDCD1LG2, ZAP70, IL1B, XCL1, HLA-DMB, CCL5, CCL19, IL12RB1, LILRB2, CD4, CD40LG, CD6, DNAJA3, HLA-DPB1]
GO:0046069;cGMP catabolic process;11.0;1.0;0.9324289523296623;9.628524252492122;5918.161003974418;7.9853141584524145;0.19807552280391336;0.8407982897480031;[PDE5A]
GO:0010936;negative regulation of macrophage cytokine production;8.0;1.0;0.875;9.628524252492122;311.05347994333346;8.16763571524637;0.010410680043746014;0.7926932703116032;[TGFB2, TGFB1, IRAK3]
GO:0030949;positive regulation of vascular endothelial growth factor receptor signaling pathway;7.0;1.0;0.8509193652572005;9.628524252492122;213.0397923327438;7.069023426578259;0.0071302501260115695;0.7124295520356204;[IL1B, ITGB3]
GO:2000353;positive regulation of endothelial cell apoptotic process;9.0;1.0;0.896240625180289;9.628524252492122;129.82178199018807;6.943860283624253;0.00434501821119318;0.7513499630073597;[FASLG, THBS1, CD40LG, CCL2, PLCG1]
GO:0050714;positive regulation of protein secretion;8.0;0.6467165523344657;0.6983582761672329;8.730582659286164;381.48337166918856;4.304802954008995;0.01276790513702299;0.5951478232618299;[TNF, PYCARD, CLEC5A, F2R, GOLPH3L, MIF, ADAM9, BLK, CD274, NLRP3, TGFB2, TGFB1, FZD5, ORM1, LRRK2, PTPN22, FFAR2, HAVCR2, CHUK, SYK, IL17RB, MMP12, TLR1, FGR, IL1B, IGHD, TLR8, TLR4, TLR2, CD58, CCL19, NR1H2, MAPK14, CD2, NLRP12, CD244, IL17A]
GO:1902043;positive regulation of extrinsic apoptotic signaling pathway via death domain receptors;10.0;0.9326813400603323;0.8815816818910864;9.589303539338841;424.7653704329427;6.943860283624253;0.014216514684375884;0.7703503496879909;[MAL, TIMP3, THBS1, ATF3]
GO:0038027;apolipoprotein A-I-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;8.16763571524637;8.87013979980389E-4;0.7408135829017477;[ABCA1, ITGB3]
GO:0000902;cell morphogenesis;4.0;0.6260725219892441;0.563036260994622;7.923776160253697;43.26261951924051;4.420487353008457;0.0014479609414792109;0.47606392880653703;[CYFIP1, COL12A1, SPINT2, CDH5, C1GALT1C1, CDH3, CDH1, MEF2C, ACTN1, COL23A1, CLDN3, SLC1A3, EPB41L5, NCKAP1L, ST14, TGFB2, BCL11B, BCL6, NOX4, NRP1, COL14A1, ITGB3, GP1BA, PALLD, COL6A3, PDPN, SLITRK6, FLNA, LAMB1, MAPK14, GRHL2, TEK]
GO:0045652;regulation of megakaryocyte differentiation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;68.9575807315309;5.845247994956144;0.0023079481692908138;0.6498456195510879;[ITGA2B, HMGB2, THBS1, NFE2, MEF2C, GP1BA, PRKCQ, MYL9, PF4]
GO:0003065;positive regulation of heart rate by epinephrine;9.0;0.8933024483968273;0.8428918493787028;9.503361109538115;125.79105564708263;9.777073627680469;0.004210113427907638;0.896240625180289;[TPM1]
GO:0007266;Rho protein signal transduction;8.0;0.9326813400603323;0.8413406700301662;9.523163736834295;29.60642063139588;5.334422371190153;9.9090025448413E-4;0.6478026081386739;[CELSR1, ARHGAP6, ARHGAP4, EPS8, PAK1, ARHGDIA, PDPN, ARHGDIB, RAC2, EPS8L1, CHUK, RHOG, RHOH, BCL6, AGTR1, RHOU]
GO:0009967;positive regulation of signal transduction;6.0;0.44130843764162375;0.5437745314109563;6.712834686611667;140.23187634019237;2.4492930892588385;0.004693434700611163;0.44837727507861835;[, SLA2, AKT1, ATF3, FPR1, FPR2, SLC30A10, IQGAP3, PDGFD, PDGFC, SFN, LYN, JUN, JAG1, JUP, NOX4, GPR18, EZH2, ARHGAP6, ARHGAP4, JPH2, GPR37, DUSP6, MMP12, NTF3, FLNA, BIK, LRG1, PKN1, LGR4, CTGF, RUVBL1, MAL, S100A8, LY96, TNFRSF11A, TNFRSF10B, NFKB1, CXCL10, CXCL11, PTPRC, MYD88, LRRK2, ITGB3, FASLG, HHEX, ADAMTS20, ACPP, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, FYN, SH2B1, TIE1, PTPN6, FCGR2B, TNFSF11, EPHB1, ACTN4, MIF, BTC, SFRP2, EPHA3, NAIP, TGFA, CD19, TSPAN5, PAG1, CCR1, TNFSF14, TNFSF12, PTK2, CD28, CD24, NRP1, CD3E, CTSH, CCR7, CD36, SYK, GAB1, BANK1, IL1B, KIT, GNAI2, PAK1, PPP1CA, NLRP12, IL18R1, CD86, CD80, IL6R, PDGFRB, CARD11, RASGRP4, CAV2, CAV1, INHBA, GH1, TNFAIP3, GHR, NUP62, MYOCD, MMP9, ELF3, CHI3L1, EGF, MAPK14, CD4, TEK, CYFIP1, PHB2, EPS8, PROK2, SEH1L, ICOS, ELANE, NDFIP2, FZD5, PLK2, TGFB1I1, TIMP3, HAVCR2, FCRL2, FCRL3, NFAM1, HBEGF, ENG, CCL13, GPNMB, CCL19, CCL18, CCL23, GSN, CCL20, CARD9, G0S2, SULF2, PF4, TNF, FGF5, PYCARD, CDH3, GRAP2, MEN1, MAP2K2, CD180, F2R, ADAM9, NACC2, DRD4, MAP2K6, CSPG4, CCDC22, LAT, PLEKHF1, TREM2, PTPN22, CHUK, LCK, XCL1, NLGN1, CSK, P2RX5, PPP2R1A, SKP2, IL1R1, POR, TP53BP2, SH2D1A, MARCO, ITM2C, IFNA2, PRL, ESM1, MAP4K1, ZDHHC17, VAV1, TLR1, TLR7, TLR6, TLR5, TLR4, TLR2, CXCR4, SORBS1, CD40LG, F2RL3, GOLT1B, GHSR, C5AR1, ADRB2, STAP1, TGFB2, TGFB1, LIN28A, CXCL9, BLNK, ARAP1, DCN, TGFBR3, FGR, ZAP70, IFNG, PDE5A, LTF, DLL1, THBS1, TRAT1, LTBR]
GO:0003222;ventricular trabecula myocardium morphogenesis;7.0;0.8933024483968273;0.7975705894556142;9.427853557029971;28.30750056401912;7.004484905440688;9.474265687811956E-4;0.7091290490632969;[TGFB2, ENG]
GO:0045778;positive regulation of ossification;5.0;0.8436909121759173;0.712086467948879;9.377209824211215;41.729731686539594;5.370354380416217;0.0013966565652281952;0.5648811846224242;[CALCA, ADRB2, SLC8A1, IL6R, CTHRC1, MEF2C, TGFB2, TGFB1, JAG1, RUNX2, SFRP2, LTF]
GO:0051895;negative regulation of focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;270.76229412472316;7.069023426578259;0.009062170314110184;0.7365101867784198;[ARHGAP6, THBS1]
GO:0014909;smooth muscle cell migration;6.0;0.8933024483968273;0.7697715367885581;9.377209824211215;22.014357120524497;7.474488534686424;7.368007211888268E-4;0.7053660038532718;[PDGFRB, ITGB3]
GO:0048010;vascular endothelial growth factor receptor signaling pathway;8.0;0.8259837884571596;0.7879918942285797;9.186691500213083;31.002284443533863;5.572381008289503;0.0010376185600805164;0.6599718239061428;[CYFIP1, NRP1, NRP2, ITGB3, NCF4, VAV1, NCKAP1L, FYN, MAPK14, PTK2]
GO:0051497;negative regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;338.83785420150645;6.781341354126479;0.01134059804585365;0.7792270645443136;[TMEFF2, STMN1, TACSTD2, ARAP1, PFN1, ARHGAP6]
GO:0001676;long-chain fatty acid metabolic process;8.0;0.6835726970475526;0.7167863485237763;8.866384200445225;93.73125239075797;5.049685808968129;0.0031371006648681556;0.6332411671050352;[, ACSL1, ELOVL6, ACSBG1, SLC27A2, HSD17B4, PTGS2, ALOX5, PNPLA8, CYP4F2, CYP4F3, TBXAS1, PLP1]
GO:0051891;positive regulation of cardioblast differentiation;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;375.85471496252956;8.16763571524637;0.012579519062513271;0.7686126355688037;[TGFB2]
GO:0051496;positive regulation of stress fiber assembly;11.0;1.0;0.9324289523296623;9.628524252492122;365.07497849775285;5.926926025970411;0.012218730984170163;0.735532224928036;[NRP1, ARHGEF10L, CTGF, PAK1, TPM1, NOX4]
GO:0071363;cellular response to growth factor stimulus;5.0;0.7671156992804218;0.6737988615011312;8.935377071932177;60.394260804020476;4.247644540169047;0.0020213415578046274;0.5074657511808371;[SPINT2, AKT1, PDGFRB, MEF2C, RUNX2, SPINT1, CALCA, ADAMTS12, EPB41L5, PDGFD, PLCG1, TGFB1, EGR3, CAV1, NR4A1, NOX4, NRP1, MCM7, TMEM100, ANXA1, ARG1, TNFRSF1B, PAX2, XCL1, CX3CR1, DTYMK, THBS1, CCL5, CCL2, FYN, MAPK14]
GO:0050680;negative regulation of epithelial cell proliferation;6.0;0.7307253602413294;0.6884829927108091;8.690254613899192;65.19530579150691;4.989581884898423;0.0021820282128758306;0.5782877622231366;[PRL, PTPRK, BRCA2, PHB2, TNF, DUSP10, MEN1, MEF2C, TGFBR3, CEACAM1, SFRP2, THBS1, CCL2, SFN, TGFB2, TGFB1, CAV2, CAV1]
GO:0031069;hair follicle morphogenesis;4.0;1.0;0.75;9.628524252492122;21.56700107071243;6.518977089658987;7.21828116795923E-4;0.5833807915285978;[TGFB2]
GO:0035702;monocyte homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;9.777073627680469;0.0013947181159950893;0.8231203125901445;[MPL]
GO:0018149;peptide cross-linking;7.0;0.6007507099811141;0.6512947202477576;8.117066748418225;151.15475272427284;5.69953618377475;0.005059013543235805;0.6423939107509793;[DSP, ANXA1, F13A1, THBS1, DCN, SPOCK3]
GO:0034614;cellular response to reactive oxygen species;5.0;0.7671156992804218;0.6737988615011312;9.197741336399668;144.094088465717;5.076593261888053;0.004822699464687224;0.5498582273596049;[TNFAIP3, PTPRK, IL18RAP, MYB, AKT1, ANXA1, CHUK, ARG1, TPM1, FOS, MMP9, PAX2, DNM2, BTK, PCNA, FOXO1, PDGFD, JUN, EZH2]
GO:0034976;response to endoplasmic reticulum stress;4.0;0.6799073451904818;0.5899536725952409;8.284789505791027;28.997869804256865;4.300610075748959;9.705326059599744E-4;0.4699333992726228;[TLN1, ATF3, JUN, WFS1, TNFRSF10B, EIF2S1, FKBP14, THBS1, CCL2, PSMC6, PSMC2]
GO:0051897;positive regulation of protein kinase B signaling;8.0;1.0;0.875;9.628524252492122;238.41769229280743;4.7664383335842135;0.007979625599047746;0.6187558780415471;[CD86, CD80, TNF, FGF5, TNFSF11, CCR7, PDGFRB, GAB1, VAV1, BTC, LCK, KIT, CHI3L1, HBEGF, ENG, THBS1, CD19, FYN, CCL19, ICOS, TGFB1, TRAT1, EGF, PTK2, LIN28A, CD28, NOX4, TEK]
GO:0043406;positive regulation of MAP kinase activity;12.0;0.7043150770688792;0.8002778511245842;9.369013057007038;2605.6877929993507;4.201124524534153;0.08721002546492271;0.6629660161470909;[, TNF, PROK2, TNFSF11, PDGFRB, MAP2K2, F2R, MIF, ADAM9, C5AR1, FPR1, TGFA, TNFRSF11A, IQGAP3, PDGFD, PDGFC, ELANE, DRD4, MAP2K6, TGFB1, FZD5, GH1, NOX4, CSPG4, CD24, EZH2, LRRK2, GHR, MAP4K1, SYK, DUSP6, IL1B, KIT, PDE5A, TLR6, TLR4, CXCR4, THBS1, PAK1, NTF3, CSK, CCL19, EGF, MAPK14, CD40LG, PKN1]
GO:1904753;negative regulation of vascular associated smooth muscle cell migration;9.0;1.0;0.896240625180289;9.628524252492122;245.4091710939714;7.9853141584524145;0.008213624102600289;0.8046099625986299;[MEF2C, MYOCD, TPM1]
GO:0008284;positive regulation of cell proliferation;5.0;0.5587538620495764;0.5696179428857084;7.270369308343265;43.45254999490143;2.9881018846882994;0.0014543177435732513;0.44305268120482816;[PID1, TFRC, MYB, HOXA3, AKT1, PROK2, MEF2C, CLDN7, AGTR1, PRKCQ, ATF3, HHLA2, IQGAP3, PDGFD, PDGFC, NCKAP1L, PLCG1, ELANE, LYN, JUN, CDC6, CDKN1A, TIMP1, HLA-DPA1, HAVCR2, ANXA1, ARG1, FCRL3, PAX2, MMP12, HBEGF, PTAFR, KCNA5, PTGS2, HLA-DMB, EPCAM, NTF3, FLNA, CCL19, IL12RB1, IL12RB2, LRG1, HLA-DPB1, CHRM1, TNC, TNF, CTGF, FGF5, PYCARD, CDH3, F2R, MSH6, CD274, BLM, CALCRL, TNFRSF11A, CORO1A, NACC2, CXCL10, CXCL12, PTPRC, BCL6, ITGB3, FASLG, TNFSF13B, LBH, XCL1, CX3CR1, SMARCD3, LRP2, CCL5, CTHRC1, KLF5, DNAJA3, PTPN6, TCL1A, EDNRB, SKP2, ICOSLG, FLT3LG, MIF, RUNX2, BTC, SFRP2, TGFA, PKHD1, EGR1, EGR3, TNFSF12, PTK2, BST1, CD28, CD24, CD320, NRP1, NRP2, PRL, CD3E, ESM1, RAC2, CTSH, CCR2, SYK, RHOG, PDCD1LG2, AVPR1A, HCK, CEACAM6, IL1B, KIT, GNAI2, PAK1, CXCR2, LILRB2, CD40LG, CD86, CD80, SIRPG, MPL, IL6R, PDGFRB, GHSR, CCNE1, PRTN3, CARD11, C5AR1, LTBP3, DPP4, TGFB2, TGFB1, CAV2, NR4A1, LIN28A, HMGB2, TNFAIP3, LAMC2, CXCL5, MYOCD, GLP2R, MMP9, TGFBR3, ZAP70, IFNG, NDUFS4, LTF, DLL1, THBS1, S1PR3, EGF, LAMB1, MAPK14, MEIS2, TSHR, CD4, CD6, TEK]
GO:0097191;extrinsic apoptotic signaling pathway;6.0;0.8259837884571596;0.7361122068187242;9.223059144383958;51.05903939735586;5.277263957350204;0.0017089000984773794;0.5929998367869052;[FASLG, TNF, IL6R, DCC, TNFRSF1B, IFNG, IL1B, BCL2A1, TGFB2, TGFB1, SORT1, TNFSF12, G0S2, TNFRSF10B, INHBA]
GO:0045787;positive regulation of cell cycle;5.0;0.5265193887476639;0.5535007062347522;7.230628979693751;42.184038669436575;3.8238302933926853;0.0014118618110960173;0.4857918708913159;[, CCNH, PHB2, CHEK1, AKT1, TAS2R13, FLT3LG, MIF, BTC, TGFA, RACGAP1, SFN, PLK2, CDC6, CD28, CDKN1A, BRCA2, ANXA1, CIT, RAD51C, IL1B, PCNA, CXCR5, KCNA5, RANBP2, RANBP1, SVIL, CCNT2, CTGF, PDGFRB, CCNE1, TGFB2, TGFB1, CNOT3, NUP62, PSRC1, SMARCD3, E2F7, SH2B1, EGF, MEIS2]
GO:0002581;negative regulation of antigen processing and presentation of peptide or polysaccharide antigen via MHC class II;6.0;0.8653626801206646;0.7558016526504768;9.427853557029971;55.710237364246;8.67846133901236;0.0018645715086227877;0.7669372290569613;[HLA-DOA, HLA-DOB, THBS1]
GO:0045785;positive regulation of cell adhesion;4.0;0.5768751454443798;0.53843757272219;7.230628979693751;21.972203539282862;3.842179432060882;7.353898787604294E-4;0.44648923483520947;[TFRC, MYB, AKT1, TNFSF11, ICOSLG, SFRP2, COL8A1, PRKCQ, HHLA2, EPB41L5, KLRK1, NCKAP1L, ICOS, ELANE, LYN, EGR3, JUP, TNFSF14, AZU1, VNN1, CD28, CD24, NRP1, CD3E, CTLA4, CCR7, CD36, CCR2, HLA-DPA1, HAVCR2, ANXA1, SYK, PDCD1LG2, VAV1, CEACAM6, IL1B, PTAFR, PAK1, HLA-DMB, PDPN, FLNA, CCL19, IL12RB1, LILRB1, LILRB2, CD40LG, HLA-DPB1, CD86, CD83, CD80, SIRPG, CXCL13, TNF, PYCARD, GRAP2, IL6R, TPM1, OLFM4, ADAM9, CARD11, CD274, BLM, CORO1A, DPP4, BTLA, NLRP3, TGFB2, TGFB1, CAV1, CXCL12, PTPRC, BCL6, DOCK5, SIRPB1, TNFSF13B, DUSP10, EMILIN2, EMILIN1, DNM2, ZAP70, IFNG, LCK, XCL1, HSPD1, CCL5, CCL2, FYN, CSK, CD4, CD6, DNAJA3, PTPN6, TEK]
GO:0045823;positive regulation of heart contraction;7.0;0.6729672293956388;0.6874029799550199;8.673012807464685;64.31364795821295;6.193554689224359;0.0021525199186360174;0.6676580400938822;[TGFB2, GCH1, TPM1, TACR3, AVPR1A, CTGF, KCNQ1]
GO:0060389;pathway-restricted SMAD protein phosphorylation;8.0;1.0;0.875;9.628524252492122;180.75330000196035;7.212124270218933;0.006049650283656873;0.7438283705770736;[TGFBR3, TGFB2, TGFB1]
GO:0045944;positive regulation of transcription by RNA polymerase II;11.0;0.5461734764479651;0.7055156905536448;8.363590748376499;1463.8556817380634;2.718315475161805;0.048993932283191266;0.5714437321440341;[EHF, PID1, SPIB, MYB, HOXA3, AKT1, HOXA7, HOXA5, MEF2A, MEF2C, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, ATF3, HOXB5, NKX2-3, JUN, JAG1, JUP, FZD5, PAX5, FOS, PAX2, MMP12, ENG, EPCAM, STAT4, NR1H2, ATAD2, GTF2H1, PSMC6, PSMC2, PF4, CCNT2, PLXND1, TNF, RUVBL2, MEN1, FOXO1, NFKB1, CXCL10, COPS5, MAFF, CIITA, HHEX, PPP1R12A, CHUK, CEBPE, ABLIM3, E2F5, E2F7, KLF1, KLF5, POU2AF1, CCNH, RPS6KA1, TNFSF11, DPF3, SLC11A1, EBF1, FLT3LG, RUNX2, SFRP2, BEX1, NHLH2, EGR1, EGR2, EGR3, BCL11B, CD28, PRL, CD3D, RGMA, IL1B, TLR4, TLR2, LILRB1, GRHL2, IL17A, ARID4A, ARID4B, HOXA10, ADRB2, NLRP3, TGFB2, TGFB1, HMGA1, INHBA, NR4A2, NFKBIA, NR4A1, TCF4, HMGB2, SLC40A1, ARHGEF10L, MYOCD, CKAP2, DCN, ELF3, TAF9, DLL1, MAPK14, MEIS2, MEIS1, RBMX]
GO:0000038;very long-chain fatty acid metabolic process;8.0;0.8933024483968273;0.8216512241984136;9.4949928598676;93.73125239075797;6.343086423195323;0.0031371006648681556;0.6993857346658935;[ELOVL4, CYP4F2, TECR, ELOVL6, ACSBG1, SLC27A2]
GO:0043525;positive regulation of neuron apoptotic process;8.0;0.8436909121759173;0.7968454560879586;9.392135474427892;179.36331192335928;5.885253329569843;0.0060031286335741505;0.6759721289664703;[FASLG, MYB, JUN, TGFB2, IL1B, UBE2M]
GO:0002576;platelet degranulation;8.0;1.0;0.875;9.628524252492122;39.85546922145481;4.956792062075433;0.0013339266872485146;0.6284905765689417;[ORM1, SERPINA1, PROS1, ITGB3, ITGA2B, F13A1, LAMP2, TIMP3, CD36, TIMP1, VWF, ACTN1, ANXA5, ACTN4, F5, PECAM1, TLN1, VCL, STXBP2, THBS1, FLNA, LYN, TGFB2, TGFB1, EGF, LHFPL2, PPBP, CD9, PF4]
GO:0048661;positive regulation of smooth muscle cell proliferation;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;63.45804869205661;5.433268205826786;0.002123883781187112;0.6009779013089371;[TNF, MYB, AKT1, SKP2, IL6R, PDGFRB, MMP9, HBEGF, CALCRL, PTAFR, PTGS2, THBS1, GNAI2, PAK1, CCL5, PDGFD, ELANE, JUN]
GO:0007229;integrin-mediated signaling pathway;6.0;1.0;0.8231203125901445;9.628524252492122;26.50247477320489;5.311165509025885;8.87013979980389E-4;0.5947335637161829;[NRP1, ITGAM, ITGB5, ITGB4, ITGB3, ITGA2B, CTGF, ADAMTS1, ITGB6, FCER1G, SYK, VAV1, FGR, HCK, CEACAM1, ADAM9, ITGA7, TLN1, PTK2, ZYX, PLP1, LAT]
GO:0034605;cellular response to heat;5.0;0.8436909121759173;0.712086467948879;9.260799472366804;50.43140892920004;5.666199763507158;0.0016878938715389536;0.5800107312719123;[CDKN1A, PTGS2, THBS1, LYN, EIF2S1, CXCL10]
GO:0051781;positive regulation of cell division;5.0;0.6763753087927167;0.6284286662572787;8.438940185618286;42.28939918509474;5.358233019883872;0.0014153881327367882;0.5642612976810992;[CXCR5, TGFA, FGF5, LBH, RACGAP1, PDGFD, NUP62, PDGFC, SVIL, TGFB2, TGFB1, TAS2R13, CDC6, PPBP, CIT, BTC, IL1B]
GO:0010757;negative regulation of plasminogen activation;10.0;1.0;0.9152410118609203;9.628524252492122;820.5340776865997;7.9853141584524145;0.027462537147443688;0.8236103492792612;[THBS1]
GO:0010759;positive regulation of macrophage chemotaxis;10.0;1.0;0.9152410118609203;9.628524252492122;998.0472698001994;7.292166977892469;0.033403743935984914;0.7881627702307852;[CCL5, C5AR1, C3AR1, MAPK14, THBS1]
GO:0051384;response to glucocorticoid;7.0;0.7671156992804218;0.7344772148974115;9.223059144383958;62.73690238121479;4.800339885259895;0.00209974766315278;0.5964089702280253;[CDKN1A, TNF, ALAD, GHSR, ANXA1, DUSP1, ANXA3, ARG1, AVPR1A, FOS, IL1B, ADAM9, ACSBG1, PCNA, ABCB4, PTAFR, PTGS2, FOXO1, IGFBP7, TGFB1, ALPL, SDC1]
GO:0001649;osteoblast differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;5.171903441692378;7.050676185779127E-4;0.5144913825262545;[TNC, FBL, AKT1, MEF2C, TPM4, RUNX2, HSD17B4, GPNMB, FIGNL1, HSPE1, PSMC2, ALPL, RBMX, LGR4]
GO:0034446;substrate adhesion-dependent cell spreading;6.0;1.0;0.8231203125901445;9.628524252492122;56.23121614310476;6.088194173566533;0.0018820081995007299;0.63447084575632;[NRP1, ITGB3, LAMB1, TEK]
GO:0010754;negative regulation of cGMP-mediated signaling;8.0;1.0;0.875;9.628524252492122;239.1998693179246;9.777073627680469;0.008005804360164796;0.875;[THBS1]
GO:0032147;activation of protein kinase activity;11.0;0.6799073451904818;0.7723826249249031;9.164951513576677;1096.8683293671154;4.034070439870987;0.03671119586651001;0.6387315022281249;[, TNF, AKT1, PROK2, TNFSF11, PRKACB, MAP2K2, SLC11A1, F2R, PRKAR1B, ADAM9, CALCA, C5AR1, FPR1, TGFA, ADRB2, IQGAP3, PRKAR2B, PDGFC, NCKAP1L, DRD4, MAP2K6, TGFB2, TNFRSF10B, CSPG4, LRRK2, ITGB3, GHR, MAP4K1, SYK, DUSP6, IL1B, KIT, CHI3L1, TLR6, TLR4, CXCR4, THBS1, PAK1, NTF3, CCL19, EGF, MAPK14, CD40LG, PKN1]
GO:0033630;positive regulation of cell adhesion mediated by integrin;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;34.61675044652454;6.943860283624253;0.0011585914843924019;0.6453503496879909;[TGFB2, SFRP2, SYK, CCL5, ADAM9, NCKAP1L, PTPN6, CXCL13]
GO:0010634;positive regulation of epithelial cell migration;8.0;0.7866048967936545;0.7683024483968273;9.383401794459138;242.52723865374625;4.901876304479318;0.00811716841739676;0.6256821821716325;[DOCK5, NRP1, NRP2, ITGB3, AKT1, CTSH, CCR6, ANXA1, ANXA3, MMP9, IFNG, ADAM9, PFN1, HBEGF, PTGS2, THBS1, EPB41L5, PLCG1, JUN, TGFB2, TGFB1, PLK2, TEK]
GO:0010595;positive regulation of endothelial cell migration;9.0;0.8259837884571596;0.8092325194088689;9.488762310116963;298.6320589889849;5.2552850506314295;0.009994946262957053;0.664996147065328;[NRP1, NRP2, ITGB3, AKT1, ANXA1, ANXA3, PTGS2, THBS1, PLCG1, TGFB1, PLK2, TEK]
GO:0050731;positive regulation of peptidyl-tyrosine phosphorylation;10.0;0.7866048967936545;0.8085434602577476;9.446202695698167;779.3603785568229;4.60092389510664;0.02608449049149353;0.6505324738215158;[NRP1, CD80, ITGB3, IFNA2, TREM2, CD3E, GHR, GRM5, CD36, IL6R, SYK, MIF, IFNG, BANK1, KIT, HBEGF, TGFA, CCL5, NTF3, STAP1, FYN, LYN, TGFB1, ACE, EGF, GH1, CD4, CSPG4, CD24]
GO:2000379;positive regulation of reactive oxygen species metabolic process;6.0;0.7763722522362496;0.7113064387082693;9.253830803050711;112.71770282919289;5.299736813202263;0.0037725600743465397;0.5941490996802742;[CDKN1A, PID1, ITGAM, TNF, AKT1, CD36, CD177, PDGFRB, DNM2, IFNG, IL1B, AGTR1, TLR6, TLR4, FPR2, PTGS2, THBS1, GNAI2, KLRK1, TGFB1, AGXT2, MAPK14, NOX4, PTX3]
GO:0010751;negative regulation of nitric oxide mediated signal transduction;8.0;1.0;0.875;9.628524252492122;239.1998693179246;8.67846133901236;0.008005804360164796;0.8188169164668168;[THBS1]
GO:0045715;negative regulation of low-density lipoprotein particle receptor biosynthetic process;8.0;1.0;0.875;9.628524252492122;494.7516452988549;8.67846133901236;0.016558892320579825;0.8188169164668168;[ITGB3]
GO:0032781;positive regulation of ATPase activity;6.0;0.7508913569872202;0.6985659910837546;8.781226392104918;51.416896668601964;5.8067817141283475;0.0017208772592953517;0.6200793994936333;[TPM1, ATP1B2, ATP1B1, DNM2, PFN1]
GO:0048666;neuron development;4.0;0.6696747006330769;0.5848373503165385;8.088079211544972;32.15320660831846;4.814228997420562;0.001076138889173156;0.4961998948126311;[ROBO2, GABRB1, FMR1, MEF2C, TGFB2, GABRA5, SLC4A7, UQCRQ]
GO:0001780;neutrophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;8.16763571524637;0.0013947181159950893;0.7408135829017477;[ANXA1, MTHFD1, PDE4B, MPL, JAM3]
GO:0043536;positive regulation of blood vessel endothelial cell migration;10.0;0.9326813400603323;0.8815816818910864;9.584072489921288;355.43002650478036;5.8067817141283475;0.011895923120858621;0.7122000987644093;[NRP1, PTGS2, THBS1, AKT1, PLCG1, TGFB1, ANXA1, PLK2]
GO:1903955;positive regulation of protein targeting to mitochondrion;10.0;0.9326813400603323;0.8815816818910864;9.597752593825367;662.5702871444865;6.311337724880743;0.022175631236180954;0.7380031166185408;[ABLIM3, RAC2, FZD5, RHOU]
GO:0051795;positive regulation of timing of catagen;8.0;1.0;0.875;9.628524252492122;253.1002415443206;8.67846133901236;0.008471037309059454;0.8188169164668168;[TGFB2]
GO:0050748;negative regulation of lipoprotein metabolic process;7.0;0.8259837884571596;0.7639112594857803;9.474373572664863;288.58086877261815;8.390779266560578;0.00965854197189917;0.7800242071602487;[ITGB3]
GO:0030593;neutrophil chemotaxis;9.0;1.0;0.896240625180289;9.628524252492122;130.2972973825895;5.382624473008031;0.004360933283440787;0.671508291047556;[CXCL6, CCL13, CXCL9, CSF3R, C5AR1, CXCL1, CXCL13, CXCL3, CXCL2, CXCL5, LGALS3, CCL8, CXCR1, CCL7, CCL5, CXCR2, CCL4, PDE4B, CCL2, CCL1, NCKAP1L, CCL19, CCL18, CCL23, TGFB2, CXADR, FCER1G, SYK, CCL20, PPBP, VAV1, CXCL10, CXCL11, IL1B, XCL1, S100A8, PF4]
GO:2001237;negative regulation of extrinsic apoptotic signaling pathway;9.0;0.8436909121759173;0.8180860812682478;9.50592193039979;358.6811287979994;5.152100814396198;0.012004734588810557;0.6597193004257005;[NRP1, HMGB2, TNFAIP3, FASLG, TNF, LGALS3, AKT1, SFRP2, IL1B, CX3CR1, THBS1, FYN, TNFRSF10B, PF4]
GO:0010888;negative regulation of lipid storage;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;46.28121162512291;6.8867018697843045;0.001548990502706573;0.6753065664753021;[ABCA1, NR1H2, ITGB3, TNF, NFKBIA]
GO:0050900;leukocyte migration;5.0;0.6023560406934092;0.5914190322076249;8.01908634005802;26.939797568556347;3.896540641279769;9.016507803758389E-4;0.4895102814636384;[CSF3R, PROS1, SIRPG, CXCL13, CXCL16, VPREB3, EPS8, LGALS3, VPREB1, EDNRB, C3AR1, TNFSF11, IL6R, SLC16A3, CD177, CXADR, ATP1B2, MIF, ATP1B1, PRTN3, S100A8, GYPA, CALCA, SDC2, C5AR1, FPR1, FPR3, FPR2, TNFRSF11A, CORO1A, NUP85, INPP5D, IGLV1-44, NCKAP1L, PLCG1, IGHA1, ELANE, NKX2-3, LYN, CCR1, TGFB2, TGFB1, GPR15, CAV1, TNFRSF10B, AZU1, DEFA1, PPBP, GP6, SELE, CXCL10, CXCL11, SDC1, IGKV3-20, IGHM, CXCL6, CXCL9, ITGAM, ITGB3, CXCL1, SLC7A11, CXCL3, CXCL2, TREM1, CXCL5, PDE4B, OLR1, FFAR2, CCR7, CCR6, CCR5, CCR2, ANXA1, FCER1G, SYK, MMP9, VAV1, SLC7A5, ZAP70, HCK, CEACAM1, SLC7A7, SLC7A8, CEACAM6, LCK, IL1B, KIT, PECAM1, XCL1, CX3CR1, CCL13, CXCR5, CXCR4, CCL8, IGKC, CXCR1, CCL7, EPCAM, CCL5, CXCR2, CCL4, CCL2, CCL1, FYN, CD58, CCL19, CCL18, JAM2, JAM3, CCL23, CCL20, CD2, NLRP12, PTPN6, TEK, CD244, PF4]
GO:0030199;collagen fibril organization;5.0;1.0;0.7902410118609202;9.628524252492122;53.964823970696955;5.9928839937622085;0.0018061540931107725;0.5967173779995258;[TGFB2, COL14A1, COL11A1, COL12A1, SFRP2]
GO:0001938;positive regulation of endothelial cell proliferation;7.0;0.8933024483968273;0.7975705894556142;9.461470167828956;87.3065775231622;5.277263957350204;0.0029220725788817177;0.6207988894539612;[NRP1, NRP2, ITGB3, HMGB2, AKT1, PLCG1, GHSR, JUN, EGR3, ARG1, CAV2, TNFSF12, NR4A1, LRG1, CXCL12, AGTR1, TEK]
GO:0010002;cardioblast differentiation;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;46.83293193138774;8.16763571524637;0.001567456084841218;0.7079342821725234;[TGFB2]
GO:1990959;eosinophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;9.777073627680469;0.0013947181159950893;0.8231203125901445;[MPL]
GO:0010763;positive regulation of fibroblast migration;8.0;0.9326813400603323;0.8413406700301662;9.567899630675686;201.49065414776382;7.379178354882098;0.006743710864509851;0.7523715242355574;[PAK1, TGFB1, AKT1, THBS1, SLC8A1]
GO:0055118;negative regulation of cardiac muscle contraction;9.0;0.811012628672052;0.801746939516315;9.466005322994347;171.6071423008873;7.9853141584524145;0.005743536616409487;0.8046099625986299;[KCNE3, PDE5A]
GO:0030511;positive regulation of transforming growth factor beta receptor signaling pathway;8.0;1.0;0.875;9.628524252492122;345.4564576873422;6.518977089658987;0.011562116748168153;0.7083807915285978;[MYOCD, TGFB1I1, THBS1, TGFBR3, LRG1, MEN1]
GO:0007050;cell cycle arrest;6.0;0.811012628672052;0.7286266269261705;9.292052015870908;55.61614271062087;4.7664383335842135;0.0018614222452456451;0.5668761906316916;[CDKN1A, DUSP1, MSH2, IFNG, THBS1, GAS2L1, MAP2K6, BARD1, TGFB2, TGFB1, CDKN2C, DHCR24, INHBA, JMY]
GO:1905221;positive regulation of platelet formation;8.0;1.0;0.875;9.628524252492122;650.421897388122;9.777073627680469;0.021769035563876396;0.875;[MPL]
GO:0040037;negative regulation of fibroblast growth factor receptor signaling pathway;7.0;0.8933024483968273;0.7975705894556142;9.517298617381897;298.26786127592857;7.004484905440688;0.00998275689325772;0.7091290490632969;[THBS1, SULF2]
GO:0045726;positive regulation of integrin biosynthetic process;7.0;0.9326813400603323;0.8172600352873667;9.574457031221845;213.12394044174204;8.67846133901236;0.00713306648749136;0.7947362817240173;[TGFB2]
GO:0045727;positive regulation of translation;8.0;0.6634067003016617;0.7067033501508309;9.123968241739727;1032.6861465930526;5.104244793218563;0.03456307596927652;0.6360313160968547;[FMR1, TNF, PTAFR, THBS1, CCL5, LIN28A, CD28, EIF3E, EIF3D]
GO:0060282;positive regulation of oocyte development;8.0;0.8436909121759173;0.7968454560879586;9.4949928598676;340.18021936709135;8.390779266560578;0.01138552579989556;0.8041048419030481;[PDE5A]
GO:0007179;transforming growth factor beta receptor signaling pathway;8.0;0.7586651285174919;0.754332564258746;9.05316010758856;29.903672154863813;5.2552850506314295;0.0010008489954655988;0.6437555218850388;[ITGB5, PTPRK, CDH5, FOS, TGFBR3, ADAM9, JUN, TGFB2, TGFB1, USP9Y, PTK2, ZYX]
GO:0043149;stress fiber assembly;8.0;1.0;0.875;9.628524252492122;75.13737719114397;7.292166977892469;0.00251478039533833;0.747921758369865;[ITGB5, ZYX, SORBS1]
GO:0042730;fibrinolysis;9.0;1.0;0.896240625180289;9.628524252492122;252.8988266382142;6.7325511899570465;0.008464296133413719;0.740543606130341;[PROS1, GP1BA]
GO:0043547;positive regulation of GTPase activity;6.0;0.9326813400603323;0.7894609826203107;9.523163736834295;49.33745512692421;3.758480413184235;0.001651280222271285;0.5153291757075998;[LLGL2, RACGAP1, NCKAP1L, JUN, EZH2, ARHGAP9, DENND1B, NRP1, ARHGAP6, ARHGAP4, CCR7, RHOG, GMIP, VAV1, CCL13, NTF3, CCL19, CCL18, RANBP2, RANBP1, CCL23, CCL20, SIPA1, CXCL13, RGS1, ARHGDIA, ARHGDIB, F2R, TSC2, ACAP1, PRTN3, ARHGAP15, ADAP2, EVI5, CAV2, ARHGAP25, TBCK, ARHGAP30, LRRK2, TAGAP, TBC1D9, ARAP3, ARAP1, ALDH1A1, XCL1, ASAP2, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1]
GO:1990960;basophil homeostasis;6.0;1.0;0.8231203125901445;9.628524252492122;41.67181410794555;9.777073627680469;0.0013947181159950893;0.8231203125901445;[MPL]
GO:0009749;response to glucose;7.0;0.8933024483968273;0.7975705894556142;9.405380701177911;32.95598622603122;4.917261223318797;0.001103007200523252;0.6023883328937558;[SLC8A1, CTGF, MEN1, RMI1, PAX2, IL1B, THBS1, EGR1, EIF2B3, TGFB1, LIN28A, NOX4]
GO:0048566;embryonic digestive tract development;5.0;0.9326813400603323;0.7565816818910864;9.4949928598676;33.609109414970646;7.004484905440688;0.001124866645884346;0.6484506956670166;[TGFB2, TNF]
GO:0030509;BMP signaling pathway;11.0;0.7090535922965819;0.7869557484779532;9.133828010656014;282.55034729266697;5.202362649177086;0.009456705845082177;0.6984780201431826;[TMEM100, EGR1, TGFB2, TGFB1, USP9Y, RUNX2, RGMA, TGFBR3, ENG]
GO:0043154;negative regulation of cysteine-type endopeptidase activity involved in apoptotic process;12.0;0.8653626801206646;0.8808016526504769;9.556203590912496;734.4861809891323;5.277263957350204;0.024582591483058774;0.7179998367869053;[RPS6KA1, AKT1, SERPINB9, TNFRSF1B, MMP9, PAX2, POR, SFRP2, NAIP, NLRC4, PTGS2, THBS1, SFN, TNFSF14, TNFRSF10C, TNFRSF10B, DHCR24]
GO:0043032;positive regulation of macrophage activation;7.0;0.9326813400603323;0.8172600352873667;9.5544162803384;126.59742726208806;6.641579411751319;0.004237101960174532;0.6905700452391912;[ITGAM, LRRK2, THBS1, HSPD1, STAP1, TLR6, TLR4, HAVCR2]
GO:0010613;positive regulation of cardiac muscle hypertrophy;8.0;0.8933024483968273;0.8216512241984136;9.485423408851448;95.57844489853944;6.444869117505266;0.003198924535738274;0.7045909063862833;[MEF2A, TRPC3, PTK2, PDE5A]
GO:0071456;cellular response to hypoxia;6.0;1.0;0.8231203125901445;9.628524252492122;103.24589989147204;5.104244793218563;0.0034555473540902374;0.5841516286869992;[MPL, PHB2, SLC8A1, AKT1, KCND2, PTGS2]
GO:0033574;response to testosterone;5.0;0.9326813400603323;0.7565816818910864;9.533214072687796;91.03892825708995;6.063501560976162;0.003046990999048697;0.6003287636709002;[THBS1, PLN, DUSP1, NASP]
GO:0048041;focal adhesion assembly;8.0;1.0;0.875;9.628524252492122;92.53238439646684;6.599019797332524;0.0030969756320103773;0.712474179321389;[ACTN1, PTPRK, SORBS1, ARHGAP6]
GO:0032369;negative regulation of lipid transport;6.0;0.6281612110245125;0.6372009181024008;8.242229891372231;82.88956312991112;6.558197802812269;0.0027742390821944756;0.6585068532133508;[EGF, NR1H2, CYP4F2, ITGB3, THBS1, NFKB1, AKT1]
GO:0060271;cilium assembly;6.0;0.8653626801206646;0.7558016526504768;9.405380701177911;137.68250629835126;4.347727998726029;0.00460810957959482;0.5454633246350222;[PKHD1, ABLIM3, FLNA, GSN]
GO:0060395;SMAD protein signal transduction;5.0;1.0;0.7902410118609202;9.628524252492122;23.17027026302992;5.734022359845919;7.75488093814194E-4;0.5834791820027497;[JUN, TGFB2, TGFB1, INHBA, FOS]
GO:0043277;apoptotic cell clearance;7.0;1.0;0.8509193652572005;9.628524252492122;28.437470009997963;6.8867018697843045;9.517765291732001E-4;0.7031056191423581;[LRP1, ITGB3, MARCO, CD36]
GO:0045214;sarcomere organization;7.0;1.0;0.8509193652572005;9.628524252492122;33.95844942788184;6.063501560976162;0.0011365587417308835;0.6610071170671804;[TPM1, KRT19]
GO:0060317;cardiac epithelial to mesenchymal transition;6.0;0.7980440201809971;0.722142322680643;9.0094850440859;24.75510523691153;6.481236761676141;8.285310941311355E-4;0.6545710619905948;[TGFB2, TMEM100, TGFBR3, ENG]
GO:1904706;negative regulation of vascular smooth muscle cell proliferation;7.0;1.0;0.8509193652572005;9.628524252492122;80.8833163751231;6.8867018697843045;0.0027070918088165762;0.7031056191423581;[MEF2C, CDKN1A, MYOCD, TPM1]
GO:0010629;negative regulation of gene expression;6.0;0.471430776349301;0.558835700764795;6.738152494595957;59.04642522059629;2.349334787147576;0.001976230713800692;0.44326540286011196;[EHMT2, SLA2, AKT1, MEF2A, MEF2C, ATF3, IQGAP3, JUN, PKIG, EZH2, MMP12, BTAF1, FLNA, LGR4, GMNN, CTGF, FOXO1, NFKB1, CIITA, LRRK2, FASLG, HHEX, FYN, E2F7, EIF3E, UXT, MIF, SFRP2, KCNQ1, NAIP, PCBP3, CCR1, EGR1, MSR1, CD28, PTPRK, CD3E, CD36, BANK1, IL1B, CCNE1, CALCA, CAV1, HMGA1, MXD1, HMGB2, MYOCD, ELF3, FBP1, PHB2, MYB, HOXA7, HOXB4, HOXB3, PRDM16, ELANE, BARD1, NDFIP2, CDKN1A, HAVCR2, PAWR, PAX5, PAX2, AES, ENG, NR1H2, FMR1, TNF, DACH1, MEN1, TLE4, MAP2K2, NACC2, WFS1, LSM5, LSM3, BCL6, CNOT3, PTPN22, EMILIN1, CR1, RFC1, PTBP2, XCL1, NLRC4, RBBP8, ZNF503, KLF8, KLF5, DNAJA3, ZNF608, EDNRB, PPP2R1A, MAGOH, DPF3, IL1R2, RUNX2, BCL11A, IFNA2, XPO1, MLH1, ARID4A, CHCHD3, BASP1, TGFB2, TGFB1, CBX4, EIF2S1, NR4A2, LIN28A, CREBZF, IFNG, PFDN5, THBS1, MEIS2, RBMX]
GO:0002687;positive regulation of leukocyte migration;8.0;0.6634067003016617;0.7067033501508309;8.963547948898873;238.70113796770806;4.956792062075433;0.007989112270702124;0.6284905765689417;[CXCL6, CXCL9, ITGA2B, CXCL1, CXCL13, CXCL3, CXCL2, TNF, CXCL5, PYCARD, LGALS3, C3AR1, RAC2, CCR7, CCR6, IL6R, CCR2, IL1R1, IL1B, XCL1, C5AR1, PTAFR, FPR2, PLA2G7, THBS1, CCL8, CCL7, CCL5, PDGFD, CXCR2, CCL4, CCL1, NCKAP1L, CCL19, S100A14, ELANE, CCR1, TGFB1, TNFSF14, CCL20, PPBP, MAPK14, CXCL10, CXCL11, CXCL12, PF4]
GO:0032914;positive regulation of transforming growth factor beta1 production;7.0;0.9326813400603323;0.8172600352873667;9.541512875502493;85.62186638127122;7.9853141584524145;0.0028656868131042177;0.7592887026755414;[THBS1]
GO:0006888;ER to Golgi vesicle-mediated transport;6.0;1.0;0.8231203125901445;9.628524252492122;49.13394272044514;4.493869898942481;0.001644468845175705;0.5529370282083849;[, PROS1, NRBP1, COPB2, TGFA, SPTA1, SERPINA1, SPTAN1, TMED6, F5, RAB33B, GOPC]
GO:0051056;regulation of small GTPase mediated signal transduction;7.0;0.6799073451904818;0.6908730378524415;8.647694999480395;45.070113835906206;4.018171853803189;0.001508456149618737;0.5564088607247961;[EPS8, ARHGDIA, STMN1, ARHGDIB, PDGFRB, F2R, TSC2, ARHGAP15, RASGRP4, RACGAP1, ABCA1, TGFB2, ARHGAP25, ARHGAP30, BCL6, GPR18, ARHGAP9, NRP1, ARHGEF10L, ARHGAP6, ARHGAP4, NUP62, PSD3, TAGAP, RAC2, RALGPS2, PLEKHG1, RHOG, ARAP3, RHOH, ARAP1, GMIP, VAV1, DNM2, RHOU, FBP1, FGD3, FGD4, EPS8L1, SIPA1, F2RL3]
GO:0048333;mesodermal cell differentiation;4.0;0.8259837884571596;0.6629918942285797;8.935377071932177;21.066225782797595;7.138016298065211;7.050676185779127E-4;0.6150384854347593;[ITGB4, ITGB3, INHBA]
GO:0002605;negative regulation of dendritic cell antigen processing and presentation;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;55.710237364246;9.083926447120524;0.0018645715086227877;0.7876727335416686;[FCGR2B, THBS1]
GO:0010748;negative regulation of plasma membrane long-chain fatty acid transport;9.0;1.0;0.896240625180289;9.628524252492122;652.3932031735304;8.390779266560578;0.02183501339445399;0.8253454670833372;[AKT1, THBS1]
GO:0035987;endodermal cell differentiation;4.0;1.0;0.75;9.628524252492122;21.066225782797595;6.444869117505266;7.050676185779127E-4;0.5795909063862833;[LAMB3, ITGB5, COL11A1, LAMA3, COL12A1, COL8A1, ITGA7, LAMB1, INHBA, MMP8, MMP9]
GO:0010745;negative regulation of macrophage derived foam cell differentiation;6.0;1.0;0.8231203125901445;9.628524252492122;114.21841186311113;7.212124270218933;0.0038227874551613377;0.6919486831672181;[ABCA1, NFKBIA, NR1H2, ITGB3]
GO:0010469;regulation of signaling receptor activity;6.0;0.5916390046238794;0.6189398149020842;7.95454781892045;48.619731222684926;3.470798340732454;0.0016272586491059737;0.5006171011438312;[CXCL13, TNF, CTGF, CXCL16, FGF5, EFEMP1, VSTM1, TNFSF11, MEF2C, IFNA14, IFNA16, FLT3LG, MIF, BTC, SFRP2, IFNA10, CALCA, TGFA, ADRB2, PDGFD, PDGFC, IFNA21, TGFB2, TGFB1, JAG1, TNFSF14, TNFSF12, INHBA, PPBP, GH1, CXCL10, CXCL11, CXCL12, PNOC, OGN, CD320, IFNA5, IFNA4, NRP1, CXCL6, IFNA7, CXCL9, IFNA2, CXCL1, FASLG, PRL, CXCL3, IFNA8, CXCL2, CXCL5, TNFSF13B, TIMP1, IFNG, IL1B, XCL1, HBEGF, CCL13, NLGN1, CLEC12B, RETN, CCL8, TTR, GPNMB, CCL7, CCL5, CCL4, NTF3, CCL2, CCL1, CCL19, CCL18, CCL23, EGF, CCL20, CD40LG, CMTM2, FCGR2B, PF4, IL17A]
GO:0010862;positive regulation of pathway-restricted SMAD protein phosphorylation;10.0;1.0;0.9152410118609203;9.628524252492122;1012.5567145242198;5.905872616772578;0.033889361993245395;0.7172676121338334;[TGFB2, TGFB1, INHBA, ENG]
GO:0032874;positive regulation of stress-activated MAPK cascade;11.0;0.7980440201809971;0.8314509624201607;9.52534001625689;1523.641600475785;4.753193106834193;0.05099491317950919;0.6755074688592472;[TNF, CTGF, PYCARD, TNFSF11, CCR7, MAP4K1, SYK, IL1B, TLR6, TNFRSF11A, PAK1, CCL19, TGFB2, FZD5, CARD9, CD40LG, PKN1, LTBR, FCGR2B]
GO:0046718;viral entry into host cell;7.0;0.7671156992804218;0.7344772148974115;8.935377071932177;28.374411874040543;5.346256828837156;9.496660301113433E-4;0.6243271881103005;[SCARB2, CD86, TFRC, ITGB5, CD80, ITGB3, ANPEP, CLEC5A, ITGB6, HAVCR1, CR2, CR1, CXADR, GYPA, DPP4, NCAM1, GPR15]
GO:0008360;regulation of cell shape;6.0;0.6763753087927167;0.6613079669865028;8.690254613899192;41.77565885716001;4.6590798152637145;0.0013981937062970905;0.5613858710120996;[CYFIP1, PLXND1, EPS8, TPM1, VRK1, ARHGAP15, CORO1A, SPTA1, MYH14, PTK2, ANXA1, RHOG, ARAP3, RHOH, ARAP1, FGR, HCK, KIT, ITGA7, RHOU, CCL13, FGD3, FGD4, CCL7, PDPN, CCL2, FYN, WASF3]
GO:0014003;oligodendrocyte development;5.0;1.0;0.7902410118609202;9.628524252492122;34.09911675737102;6.558197802812269;0.001141266750656509;0.6256275524841266;[LYN, EIF2B3, TGFB1, GSN, CD9, WASF3]
GO:1905006;negative regulation of epithelial to mesenchymal transition involved in endocardial cushion formation;8.0;1.0;0.875;9.628524252492122;277.9484853312166;9.083926447120524;0.009302685666639316;0.839552420951524;[TGFB2]
GO:1902256;regulation of apoptotic process involved in outflow tract morphogenesis;9.0;0.8933024483968273;0.8428918493787028;9.503361109538115;98.20388248212778;8.67846133901236;0.0032867955689205525;0.8400575416471059;[TGFB2]
GO:0060065;uterus development;4.0;1.0;0.75;9.628524252492122;49.86610466882393;7.138016298065211;0.0016689736466849693;0.6150384854347593;[HOXA10, MYOCD, TGFB2, HOXA11]
GO:1902895;positive regulation of pri-miRNA transcription by RNA polymerase II;12.0;1.0;0.9481203125901445;9.628524252492122;1721.2385553242598;6.599019797332524;0.0576083054325737;0.7855944919115336;[JUN, TGFB2, TGFB1, KLF5, PRL, FOS]
GO:1903588;negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis;10.0;1.0;0.9152410118609203;9.628524252492122;357.96927251473664;8.390779266560578;0.011980909399638815;0.8443458537639685;[THBS1]
GO:0048699;generation of neurons;5.0;0.9326813400603323;0.7565816818910864;9.474373572664863;21.75937296335754;7.474488534686424;7.282666309192915E-4;0.6724867031240476;[TGFB2, CDH1, CIT]
GO:1905007;positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation;8.0;1.0;0.875;9.628524252492122;277.7728422204446;8.16763571524637;0.009296807049790315;0.7926932703116032;[TGFB2, ENG]
GO:0045747;positive regulation of Notch signaling pathway;7.0;0.9326813400603323;0.8172600352873667;9.56398573135455;187.6437959822434;5.926926025970411;0.006280268983073171;0.6540226378555745;[DLL1, TSPAN5, TGFB2, JAG1, ELF3, KIT]
GO:0006986;response to unfolded protein;5.0;0.8653626801206646;0.7229223519212526;9.34084218004034;23.958124258549983;5.75172193694532;8.018568580216882E-4;0.5843843391987277;[THBS1, HSPD1, HSPE1]
GO:0030326;embryonic limb morphogenesis;5.0;0.8933024483968273;0.736892236059334;9.377209824211215;43.30626768056369;5.395046993006588;0.0014494218061579028;0.5661439659786197;[AFF3, HOXA11, HOXA10, TGFB2, RUNX2]
GO:0030449;regulation of complement activation;8.0;0.6873818243518346;0.7186909121759173;9.298282565621545;245.7676390307622;5.076593261888053;0.008225621701844479;0.6346172154986847;[C1QA, PROS1, C5AR1, IGHG1, IGKC, CD19, IGLV1-44, C3AR1, CR2, CR1, IGKV3-20]
GO:2001027;negative regulation of endothelial cell chemotaxis;10.0;0.9326813400603323;0.8815816818910864;9.593432932680852;484.3135532944439;8.390779266560578;0.016209538774865105;0.8443458537639685;[CXCL13, THBS1]
GO:0035338;long-chain fatty-acyl-CoA biosynthetic process;8.0;1.0;0.875;9.628524252492122;500.3176215265477;6.8867018697843045;0.016745180535867314;0.7271862538851576;[ACSL1, TECR, ELOVL6, ACSBG1]
GO:0010951;negative regulation of endopeptidase activity;10.0;0.7671156992804218;0.7987988615011312;9.446202695698167;500.3238742612354;4.2676852910524925;0.016745389809270216;0.6334906361130068;[PROS1, SPINT2, RPS6KA1, AKT1, POR, SFRP2, SPINT1, SLPI, NAIP, SFN, TNFSF14, TNFRSF10C, CRIM1, TNFRSF10B, DHCR24, SERPINA1, TIMP3, TIMP1, CR1, SERPINB9, TNFRSF1B, MMP9, PAX2, COL6A3, LTF, SERPINB10, NLRC4, PTGS2, THBS1, SPOCK3]
GO:0071356;cellular response to tumor necrosis factor;6.0;1.0;0.8231203125901445;9.628524252492122;81.6500655361772;4.973052582947213;0.0027327542132076126;0.5774424529526606;[PID1, PYCARD, TCL1A, AKT1, CHUK, CHI3L1, XCL1, CCL13, CALCA, ADAMTS12, THBS1, CCL8, CCL7, CCL5, CCL4, CCL2, CCL1, CD58, CCL19, CCL18, CCL23, CCL20, MAPK14, NFKB1]
GO:0050778;positive regulation of immune response;5.0;0.46069491669276497;0.5205884702073027;6.7568446276081096;78.39406295848602;3.1543373037306295;0.002623778737144363;0.45155396826539046;[, CYFIP1, TFRC, SLA2, MYB, TRBC1, C3AR1, PRKACB, MEF2C, PRKCQ, HHLA2, FPR1, FPR3, FPR2, KLRK1, NCKAP1L, S100A14, PLCG1, IGHA1, HLA-DQA1, ELANE, LYN, HLA-DRB4, FZD5, HLA-DRB1, DENND1B, ITK, CTLA4, HLA-DPA1, HAVCR2, ANXA1, NFAM1, MMP12, FCER2, TLR10, HLA-DQB1, PTAFR, UNG, HLA-DMB, CCL19, IL12RB1, CARD9, HLA-DPB1, TNF, PYCARD, IGHG1, GRAP2, CD177, LAG3, CD180, MSH6, CLEC4D, MSH2, S100A8, BLK, CD274, LY96, CLEC7A, IGLV1-44, MAP2K6, EIF2B3, BMX, NFKB1, PTPRC, HLA-DRA, LAT, MYD88, ITGAM, PTPN22, TNFSF13B, FCGR3A, CR2, CR1, CHUK, LCK, XCL1, LCP2, UNC93B1, NLRC4, CCL5, FYN, CSK, FCGR2A, PTPN6, MNDA, CD247, FCGR2B, ICAM2, ICOSLG, SLC11A1, MIF, BTK, CD1E, CD1B, CD1A, CD79B, CD79A, CD19, INPP5D, PAG1, SH2D1A, PTK2, MARCO, CD28, IGHM, CD3G, CD3E, CD3D, CTSS, FFAR2, CTSG, CCR7, MUC15, CD36, CCR2, FCER1G, SYK, LIME1, VAV1, LAT2, TLR1, HCK, IL1B, IGHD, TLR8, TLR7, TLR6, TLR5, TLR4, TLR2, C1QA, PAK1, IGKC, LILRB1, MLH1, CD86, CD80, TRAC, IL18RAP, IL6R, THEMIS, CARD11, C5AR1, STAP1, NLRP3, TGFB2, TGFB1, CAV1, NFKBIA, IGKV3-20, HMGB2, TNFAIP3, PDE4B, IRAK3, FGR, ZAP70, IFNG, LTF, COLEC12, HSPD1, CNR1, TRAT1, MAPK14, CD4]
GO:0030049;muscle filament sliding;6.0;1.0;0.8231203125901445;9.628524252492122;20.959081145343944;6.139487467954083;7.014815839862524E-4;0.6370939872166814;[TPM4, TPM2, TPM1, DMD]
GO:0010693;negative regulation of alkaline phosphatase activity;10.0;1.0;0.9152410118609203;9.628524252492122;315.7238800504293;8.67846133901236;0.010566994132243301;0.8590579283277371;[TGFB2, TNF]
GO:0051918;negative regulation of fibrinolysis;9.0;1.0;0.896240625180289;9.628524252492122;332.9628274369728;7.474488534686424;0.011143966187225523;0.7784863164434164;[THBS1]
GO:0006351;transcription, DNA-templated;9.0;0.5708408884191841;0.6816610693898811;8.449869256150476;581.393741231429;1.9872050686257638;0.019458725298619164;0.49786638480429696;[SPIB, MEF2A, MEF2C, PADI4, ATF3, JUN, HACE1, EZH2, CHAF1B, FOS, STAT4, FLNA, ZNF467, ATAD2, PKN1, CCNT2, RUVBL2, RUVBL1, FOXO1, NFKB1, CIITA, FASLG, HHEX, E2F5, E2F7, POU2AF1, CCNH, UXT, BTK, ZNF700, EGR1, EGR2, EGR3, HMGA1, MXD1, HMGB2, AFF3, NUP62, MYOCD, ELF3, CREB5, TAF9, MAPK14, EHF, PHB2, HOXA9, MYB, HOXA3, HOXA7, HOXA5, HOXA4, HOXB9, HOXB4, HOXB3, HOXB2, HOXB7, HOXB6, HOXB5, PRDM16, NKX2-3, NFE2, TGFB1I1, ZNF367, BRD2, PAWR, PAX5, PAX2, AES, GTF2H1, MEN1, TLE4, NACC2, MAP2K6, HOPX, COPS5, BCL6, CNOT3, MAFF, LBH, RFC1, SMARCD3, CEBPE, ABLIM3, POLR2E, ZNF503, POLR2I, POLR2J, POLR2K, POLR2L, KLF1, KLF8, KLF5, MNDA, ZNF608, DPF3, EBF1, NHLH2, BCL11B, BCL11A, GRHL2, ARID4A, ARID4B, HOXA11, HOXA10, CHCHD3, C5AR1, NLRP3, CBX4, NR4A2, CREBZF, KDM5D, LTF, MEIS2, MEIS1, RBMX]
GO:0030041;actin filament polymerization;7.0;0.9326813400603323;0.8172600352873667;9.548481544818586;66.55674193746657;6.409777797693995;0.0022275942554681166;0.6787156999164222;[GSN, ARHGAP6, WASF3]
GO:0038163;thrombopoietin-mediated signaling pathway;8.0;1.0;0.875;9.628524252492122;32.49393932031223;8.67846133901236;0.0010875429064040555;0.8188169164668168;[MPL]
GO:0042130;negative regulation of T cell proliferation;9.0;0.7763722522362496;0.7844267512984139;9.424925297250882;581.9323154417883;5.734022359845919;0.01947675089275457;0.6894787953221185;[CD86, CD274, CD80, GPNMB, CTLA4, HAVCR2, TGFB1, ARG1, PAWR, LILRB1, PDCD1LG2, LILRB2, XCL1, PTPN6, PDE5A]
GO:0030032;lamellipodium assembly;6.0;0.8933024483968273;0.7697715367885581;9.533214072687796;78.21732158183345;6.311337724880743;0.002617863362324714;0.6458824173477649;[CYFIP1, ABLIM3, NUP85, KIT, VCL, WASF3, SH2B1]
GO:0032695;negative regulation of interleukin-12 production;6.0;0.8933024483968273;0.7697715367885581;9.427853557029971;65.25422870398782;7.004484905440688;0.002184000309729388;0.6813299963962409;[LILRB1, IRAK3, THBS1, NFKB1, TLR8]
GO:0030036;actin cytoskeleton organization;5.0;0.6347111282356054;0.607596575978723;8.048073876931273;29.6146440060229;3.9779809732199434;9.911754834323397E-4;0.49367514382642164;[TNF, MYOZ2, PDGFRB, MEF2A, GAS2L3, CXADR, TPM1, TLN1, PFN1, LLGL2, CORO1A, EPB41L5, RACGAP1, MYH14, MYH11, NCKAP1L, CORO2A, TBCK, BCL6, NRP1, ITGB5, LMOD1, ARHGEF10L, CXCL1, ANXA1, RHOG, GAB1, RHOH, PALLD, KIT, RHOU, FGD3, FGD4, PAK1, ABLIM3, FLNA, SORBS1, KRT19, ZYX]
GO:0031643;positive regulation of myelination;7.0;1.0;0.8509193652572005;9.628524252492122;206.47068931946234;7.212124270218933;0.006910388159965925;0.7197477358342742;[WASF3]
